Gastrointestinal bleeding, also known as gastrointestinal hemorrhage, is all forms of bleeding in the gastrointestinal tract - from the mouth to the rectum. The symptoms of gastrointestinal bleeding depend on the acuteness and the source of the blood loss. Mild, chronic gastrointestinal blood loss is not likely to indicate any active bleeding; however, it can still result in an iron-deficiency anemia. Many such patients never notice any blood loss; however, it occurs in small amounts with the bowel movement and hence, it is not noticeable.
Gastrointestinal bleeding is an important concern in patients treated with direct oral anticoagulants (DOACs). Gastrointestinal bleeding is a common complication of hepatocellular carcinoma (HCC). Common etiologies include peptic ulcer disease, variceal bleeding due to portal hypertension from underlying cirrhosis and/or tumor, invasion of portal vein causing thrombosis, and portal hypertensive gastropathy. Acute or overt gastrointestinal bleeding is visible in the form of hematemesis, melena, or hematochezia. Chronic or occult gastrointestinal bleeding is not apparent to the patient and usually presents as positive fecal occult blood or iron-deficiency anemia.
Causes of gastrointestinal bleeding include gastric ulcers, artery or vein (arteriovenous) malformations, diverticulosis, cancer, or inflammatory bowel disease. Geriatric patients are at a higher risk of death due to severe GI bleeding. Increasing prevalence of upper gastrointestinal bleedings, gastric ulcers, and increasing awareness about gastrointestinal diseases are some factors that are likely to drive the Gastrointestinal Bleeding Treatment Market during the forecast period. GI bleeding is a common problem medical practitioners encounter in the emergency department and in the primary care setting. According to the National Center for Biotechnology Information, annual hospital admissions for GI bleeding in the U.S. and the U.K. have been estimated to be up to 150 patients per 100000 population with a 5% to 10% mortality rate. While GI bleeding can be potentially life-threatening, it has been witnessed that in many cases, it can be safely managed on an outpatient basis.
Request to View Brochure of Report -
The global gastrointestinal bleeding treatment market can be segmented based on product type, gastrointestinal tract division, end-user, and region. Based on product type, the gastrointestinal bleeding treatment market can be segregated into hemostasis devices, closure devices, and others. In terms of gastrointestinal tract division, the gastrointestinal bleeding treatment market can be classified into upper gastrointestinal and lower gastrointestinal. Based on end-user, the gastrointestinal bleeding treatment market can be split into hospitals, clinics, ambulatory surgical centers, and others.
In terms of region, the gastrointestinal bleeding treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for a larger share of the market, and the trend is expected to continue during the forecast period. Expansion of the market is attributed to the increasing incidence of gastrointestinal bleeding in the U.S. and approval of new products.
Comments
Post a Comment